ASCO 2020: SPARTAN Reveals Overall Survival Benefit of Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer

ARTICLES

ASCO 2020: SPARTAN Reveals Overall Survival Benefit of Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer

PRACTICE UPDATE

PUBLISHED: 09 JUNE 2020

May 31, 2020—The addition of the androgen receptor inhibitor apalutamide to androgen deprivation therapy improves overall survival (OS) among patients with nonmetastatic castration-resistant prostate cancer, according to the final results of the SPARTAN trial, presented during a virtual session as part of the 2020 International Conference of the American Society of Clinical Oncology.